Taysha Gene Therapies to Participate in Upcoming Investor Healthcare Conference and CEO Forum

Rhea-AI Summary

Taysha Gene Therapies, Inc. (Nasdaq: TSHA) announced its participation in two upcoming virtual fireside chats at major biotechnology conferences on June 22, 2021. The first event is the LifeSci Genetics Medicine Conference at 10:00 am ET, while the second is the LSX Biotech Growth CEO Forum at 1:10 pm ET, focusing on optimizing value from discovery platforms. Key executives, including the CEO and CMO, will participate in these discussions. Webcasts will be available for 60 days on Taysha's corporate website.

Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a patient-centric, pivotal-stage gene therapy company focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the central nervous system (CNS) in both rare and large patient populations, today announced its participation in virtual fireside chats at the LifeSci Genetics Medicine Conference and LSX Biotech Growth CEO Forum.

Conferences Details:

Event:			LifeSci Genetics Medicine Conference
Date:			Tuesday, June 22, 2021
Time:			10:00 am ET
Format:			Fireside chat
Participants:			RA Session II, President, Founder and CEO
			Dr. Suyash Prasad, Chief Medical Officer and Head of R&D
			Kamran Alam, Chief Financial Officer
Event:			LSX Biotech Growth CEO Forum
Topic:			“Too Much of a Good Thing Can be Wonderful: Optimizing Value From Broad Discovery Platforms Through Strategy and Strategic Partnering”
Date:			Tuesday, June 22, 2021
Time:			1:10 pm ET
Format:			Fireside chat
Participants:			RA Session II, President, Founder and CEO

Webcasts for these conferences will be available in the “Events & Media” section of the Taysha corporate website at https://ir.tayshagtx.com/news-events/events-presentations. Archived versions of the webcasts will be available on the website for 60 days.

About Taysha Gene Therapies

Taysha Gene Therapies (Nasdaq: TSHA) is on a mission to eradicate monogenic CNS disease. With a singular focus on developing curative medicines, we aim to rapidly translate our treatments from bench to bedside. We have combined our team’s proven experience in gene therapy drug development and commercialization with the world-class UT Southwestern Gene Therapy Program to build an extensive, AAV gene therapy pipeline focused on both rare and large-market indications. Together, we leverage our fully integrated platform—an engine for potential new cures—with a goal of dramatically improving patients’ lives. More information is available at www.tayshagtx.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210615005336/en/

FAQ

What are the details of the LifeSci Genetics Medicine Conference for TSHA?

Taysha Gene Therapies will participate in the LifeSci Genetics Medicine Conference on June 22, 2021, at 10:00 am ET.

When will Taysha Gene Therapies participate in the LSX Biotech Growth CEO Forum?

Taysha Gene Therapies will participate in the LSX Biotech Growth CEO Forum on June 22, 2021, at 1:10 pm ET.

What topics will be discussed by TSHA executives at the upcoming conferences?

TSHA executives will discuss optimizing value from broad discovery platforms at the LSX Biotech Growth CEO Forum.

Where can I find the webcasts for Taysha's conference presentations?

Webcasts for Taysha's conference presentations will be available in the 'Events & Media' section on their corporate website.

What is the focus of Taysha Gene Therapies?

Taysha Gene Therapies focuses on developing curative AAV-based gene therapies for monogenic diseases of the central nervous system.